Recommendation of the President – Ocrevus (ocrelizumab)
On 16 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 6/2025 on the appraisal Ocrevus (ocrelizumab) in the form for subcutaneous administration under the drug program B.29 “Treatment of patients with multiple sclerosis (ICD-10: G35)”